CDTX Cidara Therapeutics, Inc.

6.30
0  -1%
Previous Close 6.35
Open 6.35
Price To book 1.21
Market Cap 105.85M
Shares 16,801,000
Volume 82,300
Short Ratio 3.30
Av. Daily Volume 84,103

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
CD101 IV - STRIVE
Candidemia
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
  2. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  3. 3 of the Best & Worst Performing Drug Stocks of Q1
  4. Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy
  5. Cidara Therapeutics to Host Investor Day on April 6, 2017
  6. Arbutus Announces Appointment of Daniel Burgess to Board of Directors
  7. Cidara Therapeutics reports 4Q loss
  8. Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  9. Is The Cidara Therapeutics Inc (CDTX) Crash An Opportunity?
  10. Cidara Yeast Infection Gelm Fails Phase 2 Trial
  11. Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
  12. Antimicrobials Working Group Announces New Leadership Team
  13. Cidara Therapeutics Completes Enrollment in Phase 2 RADIANT Trial Evaluating Novel Antifungal CD101 Topical in Vulvovaginal Candidiasis
  14. Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
  15. Hedge Funds Aren’t Crazy About Cidara Therapeutics Inc (CDTX) Anymore
  16. Cidara Therapeutics, Inc. :CDTX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  17. Cidara Therapeutics’ Presentations at ASH 2016 to Highlight Potential Role of Novel Antifungal CD101 in Patients with Hematologic Malignancies
  18. Is Cidara Therapeutics (CDTX) Stock a Solid Choice Right Now?